Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision

J Interv Card Electrophysiol. 2013 Sep;37(3):209-11. doi: 10.1007/s10840-013-9821-7. Epub 2013 Jul 28.
No abstract available

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Anticoagulants / administration & dosage
  • Antithrombins / administration & dosage
  • Atrial Fibrillation / epidemiology*
  • Atrial Fibrillation / surgery*
  • Benzimidazoles / administration & dosage*
  • Catheter Ablation / statistics & numerical data*
  • Comorbidity
  • Dabigatran
  • Decision Making
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Evidence-Based Medicine
  • Humans
  • Premedication / statistics & numerical data*
  • Risk Factors
  • Thromboembolism / epidemiology*
  • Thromboembolism / prevention & control*
  • Treatment Outcome
  • beta-Alanine / administration & dosage
  • beta-Alanine / analogs & derivatives*

Substances

  • Anticoagulants
  • Antithrombins
  • Benzimidazoles
  • beta-Alanine
  • Dabigatran